Oncology News

Patients with hepatocellular carcinoma on a liver transplantation waitlist who had public insurance had worse waitlist outcomes compared with those who had Kaiser Permanente or other private insurance, according to data published in JAMA Network Open.

Increasing physician experience in the management of Nexavar-related adverse events has led to longer treatment duration and improved overall survival rates in patients with hepatocellular carcinoma, according to results from a nearly 10-year retrospective study.

Eureka Therapeutics has initiated a phase 1/2 clinical trial of its ET140202 Artemis T-cell therapy for the treatment of liver cancer, according to a press release.

SillaJen announced the discontinuation of a phase 3 trial designed to evaluate Pexa-Vec for the treatment of advanced liver cancer after interim analysis by the company’s independent data monitoring committee, according to a press release.

The FDA granted breakthrough therapy designation to pembrolizumab in combination with lenvatinib as first-line treatment for patients with advanced unresectable hepatocellular carcinoma who are not able to receive locoregional treatment.

The American Association for the Study of Liver Diseases Foundation has granted $3.42 million in research and career development awards to 29 researchers and clinicians to conduct liver disease research and undergo advanced hepatology training.

Results from a phase 3 study of Opdivo for unresectable hepatocellular carcinoma revealed that the drug showed a trend toward improvement in overall survival but did not meet significance for its primary endpoint, according to a press release from Bristol-Myers Squibb.

Race-matched liver transplants significantly improved OS among black patients with early hepatocellular carcinoma, according to study results published in Journal of the American College of Surgeons.

Poor oral health correlated with an increased risk for hepatobiliary cancers, including hepatocellular carcinoma, according to an analysis of data from the UK Biobank cohort.

Medivir released interim results from a phase 1a study of MIV-818 for the treatment of advanced liver cancer that showed selective effect signal on liver cancer tissue, according to a press release.